Pacific Biosciences of California (PACB) Stock Forecast & Price Target
Score
Pacific Biosciences of California, Inc. price target
| PACB | |
|---|---|
| Low | $1.35 |
| Average | $1.93 |
| High | $2.50 |
| Upside vs current price | -1.5% |
The average target of $1.93 is -1.5% versus the current PACB price of $1.96.
Pacific Biosciences of California, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 0 |
| Buy | 4 |
| Hold | 3 |
| Sell | 0 |
| Strong sell | 1 |
| Consensus | Hold |
8 analysts cover PACB.
Pacific Biosciences of California, Inc. EPS and revenue estimates
Published annual figures for PACB on this page are 2026 EPS $-0.46, 2027 EPS $-0.45. Coverage under three analysts is omitted.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-0.46 | $158.40M |
| 2027 | $-0.45 | $179.72M |
Is Pacific Biosciences of California, Inc. a buy or sell?
Of the 8 analysts covering Pacific Biosciences of California, Inc., 4 rate it a buy (0 strong buy and 4 buy), 3 rate it a hold, and 1 rates it a sell (0 sell and 1 strong sell).
The PACB consensus label is Hold, beside 4 buy-side ratings and 1 sell-side ratings.
The average target of $1.93 implies -1.5% versus the current price of $1.96.
The PACB rating block is 8 published views with a Hold label. It does not tell you whether to buy or sell.
Reading the Pacific Biosciences of California, Inc. forecast
A wide spread is the story on PACB. Targets run from $1.35 to $2.50, with $1.93 as the average.
The gap from the $1.96 price to the PACB average is -1.5%.
the Pacific Biosciences of California, Inc. does not have a single rating camp: 4 of 8 analysts are on the buy side, 3 are at hold, and 1 is on the sell side, and the published consensus is Hold.
Month by month, the PACB average target is higher ($2.50) than the quarterly average ($1.93).
With 8 analysts on PACB, the average is a small sample.
Pacific Biosciences of California, Inc. forecast questions
What is the PACB price target?
The published range for PACB is $1.35 to $2.50, with an average of $1.93. That average is -1.5% versus the current price of $1.96.
Is Pacific Biosciences of California, Inc. a buy or sell?
Of the 8 analysts covering Pacific Biosciences of California, Inc., 4 rate it a buy, 3 rate it a hold, and 1 rates it a sell. The consensus is Hold, leaving PACB at 4 buy ratings, 3 holds, and 1 sells.
What is the EPS estimate for Pacific Biosciences of California, Inc.?
Analyst EPS estimates for Pacific Biosciences of California, Inc.: 2026 $-0.46, 2027 $-0.45.
What is the revenue estimate for Pacific Biosciences of California, Inc.?
Analyst revenue estimates for Pacific Biosciences of California, Inc.: 2026 $158.40M, 2027 $179.72M.
How many analysts cover PACB?
8 analysts cover PACB. Their consensus on PACB is Hold, across those 8.